ArticleThe Journal of allergy and clinical immunology2021
Optimal human pathogenic T
Article in The Journal of allergy and clinical immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 41 citations in OpenAlex.
- Efficacy and Safety of Dupilumab in Children With Peanut Allergy: A Multicenter, Open-Label, Phase II Study.Allergy · 2025Trial
- Pathogenic type-2 immunity beyond allergy: the role of Th2 cell heterogeneity in helminth infections.Infection and immunity · 2026Review
- Review
- Immunomodulatory Effects of Huaier Extract on Th1/Th2 Polarization Through IL-33/ST2 Axis Regulation in Allergic Rhinitis Pathogenesis.Applied biochemistry and biotechnology · 2026Article
- Mixed Signals: T Cells as Architects of IgE Immunity.Immunological reviews · 2026Review
- Targeting alarmins in asthma: From bench to clinic.The Journal of allergy and clinical immunology · 2025Review
- A Phenotypically Distinct Human Th2 Cell Subpopulation Is Associated With Development of Allergic Disorders in Infancy.Allergy · 2025Article
- Single-cell and chromatin accessibility profiling reveals regulatory programs of pathogenic Th2 cells in allergic asthma.Nature communications · 2025Article
- Differential T follicular helper cell phenotypes distinguish IgE-mediated milk allergy from eosinophilic esophagitis in children.The Journal of allergy and clinical immunology · 2025Article
- IL-33 released during challenge phase regulates allergic asthma in an age-dependent way.Cellular & molecular immunology · 2025Article
- Role of human antigen-specific T cells in tolerance and IgE-mediated allergic reactions to food.Frontiers in immunology · 2025Review
- Contribution of T cell subsets to different food allergic diseases.Immunological reviews · 2024Review
- Potential Protective Factors for Allergic Rhinitis Patients Infected with COVID-19.Current issues in molecular biology · 2024Review
- The USP7-STAT3-granzyme-Par-1 axis regulates allergic inflammation by promoting differentiation of IL-5-producing Th2 cells.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- TRAF4 is crucial for ST2+ memory Th2 cell expansion in IL-33-driven airway inflammation.JCI insight · 2023Article
- Distinct trajectories distinguish antigen-specific T cells in peanut-allergic individuals undergoing oral immunotherapy.The Journal of allergy and clinical immunology · 2023Article
- A Multidisciplinary Approach for Type 2 Allergic Diseases: What Do Biologics Teach Us?Journal of personalized medicine · 2023Article
- Article
- How the Immune System Responds to Allergy Immunotherapy.Biomedicines · 2022Review
- IL-33 activates mTORC1 and modulates glycolytic metabolism in CD8Immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundIL-33 is an emerging key factor in development of allergic diseases. The IL-33 receptor (suppressor of tumorigenicity [ST2]) is a differentially expressed gene in pathogenic T
objectiveWe investigated the role of IL-33 in modulating circulating allergen-specific T-cell responses. We hypothesized that selective ST2 expression on allergen-specific CD4
methodsPBMCs from subjects with food allergy, inhalant allergy, and no allergy were obtained on the basis of clinical history and serum IgE level. A T-cell receptor-dependent CD154 upregulation assay and direct peptide major histocompatibility complex class II tetramer staining were used to profile allergen-specific CD4
resultsST2 expression on peripheral allergen-specific CD4
conclusionST2 expression on circulating CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.